ACOs Can’t Tap Into 340B Drug Discounts Provided To Member Safety Net Facilities, HRSA Clarifies
Executive Summary
The clarification could answer biopharma industry concerns about how 340B rules fit in the new Medicare accountable care organization program; HRSA also advises that drug shortage allocation plans may not discriminate against 340 providers.
You may also be interested in...
340B Manufacturer Fines Outlined In Rule, But HRSA Expects To Use Them ‘Very Rarely’
Proposed rule would implement how civil monetary penalties will be applied to manufacturers that “knowingly and intentionally” deny 340B prices to eligible health care providers.
Gaming 340B: Sen. Grassley Wants Answers On How A Hospital Bends Drug Discount Rules
The ranking member on the Senate Judiciary Committee sends a letter to the University of Alabama Hospital seeking details on how it has changed the admission status and treatment of patients to get 340B drug discounts for patients who would not have been eligible otherwise.
Drug Audits Of 340B Providers Will Be Both Random And Targeted, HRSA Says
The Health Resources and Services Administration has begun random and targeted audits of health care providers participating in the federal 340B drug discount program to help ensure products are not being diverted for other uses or resulting in manufacturers paying double discounts to Medicaid.